We are a clinical-stage biotechnology company developing treatments for age-related brain disorders. Our lead drug candidate, neflamapimod, is an investigational, orally administered small-molecule drug that readily crosses the blood brain barrier and selectively inhibits the enzyme p38α, a key driver of neuroinflammation and synaptic dysfunction.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Vertex Pharmaceuticals: exclusive license to VX-745 (August 2012; option exercised 2014); up to ~$117M in regulatory and sales milestones plus sliding low- to mid-teen royalties on net sales; NIA grant of $21.3M funding the RewinD-LB Phase 2b trial
Indications
Dementia with Lewy bodies (DLB)(Phase 2)
Recovery after ischemic stroke (RESTORE trial)(Phase 2)
Frontotemporal dementia (FTD)(Stage not disclosed)
Catalysts
— second half of 2026
— second half of 2026
— fourth quarter of 2026
Status note Lead and sole clinical candidate. Phase 2b RewinD-LB final results announced October 2025; FDA aligned November 2025 on planned single 32-week Phase 3 (~300 DLB patients without AD co-pathology). FDA Fast Track for DLB (October 2019); Orphan Drug Designation for FTD (November 2024). Strategic priority is securing a partnership to fund Phase 3.
Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.